The epidemiological and economic impact of a cell-based quadrivalent influenza vaccine in an adult population in the US: a dynamic modeling approach
Authors:
Preprint
- 21 May 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
BackgroundMutations of the H3N2 vaccine strain during the egg-based vaccine manufacturing process seem to partly explain the suboptimal effectiveness of traditional seasonal influenza vaccine. Cell-based influenza vaccines avoid such egg-adaptation, thereby improving antigenic match and vaccine effectiveness. The objective of this study was to evaluate the public health and economic impact of a cell-based quadrivalent influenza vaccine (QIVc) in adult population (18–64 years) compared to the standard egg-based quadrivalent influenza vaccine (QIVe), in the US.MethodsThe impact of QIVc over QIVe in terms of public health and costs outcomes was estimated using a dynamic SEIR transmission model. The model is age-structured and accounts for 4 circulating influenza strains (A/H1N1pdm9, A/H3N2, B(Victoria), and B(Yamagata)). It was calibrated on US attack rate and strain circulation for the seasons 2013–2018. US specific absolute vaccine effectiveness for QIVe, specific hospitalization rate, mortality rate, Quality-Adjusted Life Years (QALYs) and costs were extracted from published literature. Relative vaccine effectiveness of QIVc over QIVe for subjects 18–64 years of age was obtained from a US retrospective cohort study. Robustness of the results was assessed in univariate and probabilistic sensitivity analyses.ResultsSwitching from QIVe to QIVc in the 18–64 year-old population may prevent 5.7 M symptomatic cases, 1.8 M outpatient visits; 50K hospitalizations and 5,453 deaths annually. The switch could save 128 K QALYs and US$ 845M in direct costs, resulting in a cost-saving alternative in a 3-year time horizon analysis. Probabilistic sensitivity analyses confirmed the robustness of the cost-saving result.ConclusionsThe analysis shows that QIVc is expected to prevent a substantial number of hospitalizations and deaths, and would result in substantial savings in health care costs.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018Clinical Infectious Diseases, 2020
- Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017–2018Vaccine, 2019
- Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017–2018 influenza seasonVaccine, 2019
- Estimates of global seasonal influenza-associated respiratory mortality: a modelling studyThe Lancet, 2018
- Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strainsProceedings of the National Academy of Sciences, 2017
- A systematic review of the health economic consequences of quadrivalent influenza vaccinationExpert Review of Pharmacoeconomics & Outcomes Research, 2017
- Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesThe Lancet Infectious Diseases, 2016
- Health and economic impact of the seasonal influenza vaccination programme in EnglandVaccine, 2012
- Using Time-Use Data to Parameterize Models for the Spread of Close-Contact Infectious DiseasesAmerican Journal of Epidemiology, 2008
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008